Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

DANBURY, Conn., Sept. 21 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun.

"We are expanding VIAject(TM)'s pivotal Phase III trials into Europe to support our planned European registration of VIAject(TM)," stated Dr. Solomon S. Steiner, Chairman and CEO of Biodel. "Given the worldwide prevalence of diabetes, we are determined to establish VIAject(TM) as a global solution. Evaluating VIAject(TM)'s therapeutic profile in European patients with Type 1 and Type 2 diabetes gives us the opportunity to demonstrate VIAject(TM)'s clinical outcomes across a more diverse patient population."

VIAject(TM) is currently undergoing two pivotal Phase III clinical studies. The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients, are comparing the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin. Both studies are open label and involve a treatment regimen that is six months in duration. Clinical endpoints of both trials include non-inferiority in terms of HbA1c levels and safety.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and tw
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... SUWANEE, Ga. , Oct. 31, 2014  Digirad ... letter to PDI, Inc. (Nasdaq: PDII ), ... rejection of Digirad,s proposal to acquire the company.  ... in meaningful discussions regarding a transaction and to operate ... spend its cash, or take on additional debt, on ...
(Date:10/31/2014)... Oct. 31, 2014  Semler Scientific, Inc. (Nasdaq: ... risk assessment company that develops patented products that ... chronic diseases, today reported financial results for the ... 2014. "In the third quarter ... Murphy-Chutorian , M.D., chief executive officer of Semler.  ...
(Date:10/31/2014)... 31, 2014 Investor-Edge has initiated coverage ... ), Abbott Laboratories (NYSE: ABT ), Hologic Inc. ... RMD ), and Covidien PLC (NYSE: COV). Free research on ... . The US markets on Thursday, October 30, 2014, ... Average finished at 17,195.42, up 1.30% and the NASDAQ Composite ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5
... The delay in round two of Medicare,s controversial "competitive" ... that program,s severe design flaws. Opposition to the program ... among members of Congress where one fifth of the ... of the program. "The federal government,s ...
... Care Breast Center at the Helen F. Graham Cancer ... breast Magnetic Resonance Imaging (MRI) by the American College of ... The Christiana Care Breast Center is the only ... the breast offers valuable information about many breast conditions that ...
Cached Medicine Technology:Delay of Medicare Bidding Program for Home Medical Equipment Underscores Severe Problems with Program; Support Surges for Bipartisan Bill to Repeal the Bid Program 2Delay of Medicare Bidding Program for Home Medical Equipment Underscores Severe Problems with Program; Support Surges for Bipartisan Bill to Repeal the Bid Program 3
(Date:10/31/2014)... North Shore Eye Care today announced the ... and the addition of leading ophthalmologist, William S. Kasper, ... Shore Eye Care Medical Director, Jeffrey Martin, MD. , ... Department of Ophthalmology of Winthrop-University Hospital and has maintained ... more than 30 years. He has been named to ...
(Date:10/31/2014)... Urban Hydroponics, Inc. (OTCQB:URHY), a Nevada corporation ... signed a Binding Letter of Intent (LOI) to merge ... - Urban Cultivator Inc. (“Urban Cultivator”), BC Northern Lights ... (“W3 Metal” and together with Urban Cultivator and BC ... LOI and an earlier non-binding term sheet, Urban Hydroponics, ...
(Date:10/31/2014)... have found a drug combination that can trigger the ... way for new treatments, according to research that will ... Cancer Conference in Liverpool next week*. , When healthy ... of events culminating in self destruction. But cancer cells ... This means that cells grow out of control – ...
(Date:10/31/2014)... Melbourne, Fl. (PRWEB) October 31, 2014 ... school for boys and girls in grades 6-12, ... the potential for sports injuries and concussions, becoming ... proactively administer the ImPACT (Immediate Post-Concussion Assessment and ... As a 'Former NFL Player' lawsuit grabs the ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 FindSurrogateMother.com ... most remarkable gifts of life — building a family ... extraordinary surrogate mothers and donors with hopeful intended parents ... unforeseen circumstances. , It’s a collective aptitude of surrogate ... surrogacy lawyers, and fertility clinics that help provide these ...
Breaking Medicine News(10 mins):Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Florida Air Academy Tackling Concussions Head-On 2Health News:Florida Air Academy Tackling Concussions Head-On 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
... FLORHAM PARK, N.J., Jan. 6 Managed Health Care ... Butterfield, RN, has joined MHA, Inc. as the new ... newly created role Pegeen will have executive responsibility for ... Michael J. Sicilian, President of MHA, commented, "The creation ...
... Web-Based Community for Parents of Children with DisabilitiesNEWTON, ... community for parents of disabled children, today announced ... to assist parents of children with disabilities, the ... resource library for families. ChildRC ( www.ChildRC.com ) ...
... Inc. (TSX: IM) ("IMRIS" or the "Company") today ... Australia for its IMRISneuro surgical imaging solution, thereby ... Canberra Hospital has chosen a two-room configuration of ... a larger Australian Capital Territory infrastructure project. , ...
... Jan. 6, 2009 The Procter & Gamble Company,(NYSE: ... have reached a settlement in the lawsuit P&G,filed on ... trade dress and,patent infringement on its Olay Regenerist brands. ... Fruit of the Earth recognized the validity of,P&G,s rights ...
... means condition could be biologically driven, researchers say , , ... traumatized by sexual, physical or psychological abuse are more ... research suggests. , The study also states that ... be based in biology. The reason: There appears to ...
... PET Infusion System to Compare Techniques for Patient ... signed a research agreement with the University of ... MEDRAD Intego(TM) PET Infusion System. The researchers ... control the radioactive dose delivered during PET imaging ...
Cached Medicine News:Health News:MHA Announces Pegeen Butterfield, RN as Senior Vice President of Trade Relations 2Health News:ChildRC.com Launches The Child Resource Center 2Health News:Childhood Trauma Tied to Chronic Fatigue Syndrome 2Health News:Childhood Trauma Tied to Chronic Fatigue Syndrome 3Health News:MEDRAD Sponsors PET Research with University of Zurich 2Health News:MEDRAD Sponsors PET Research with University of Zurich 3Health News:MEDRAD Sponsors PET Research with University of Zurich 4
... System aids in the rapid, detection of ... available in vitro system that uniquely simulates ... primary hemostasis. The system measures platelet function ... environment of a partially occluded blood vessel. ...
... A complete range of automatic systems for ... 1 mL of blood. With the introduction ... the clinical diagnostic market a truly revolutionary ... technical limitation associated with the traditional ESR ...
... NEW VACUETTE® erythrocyte sedimentation rate ... help. The new generation unites the ... with whole range of additional innovations ... the erythrocyte sedimentation rate. Cost effectiveness ...
Blood sedimentation rate analysis...
Medicine Products: